Tissue-engineered Cardiac Patch for Advanced Functional Maturation of Human ESC-derived Cardiomyocytes
Overview
Affiliations
Human embryonic stem cell-derived cardiomyocytes (hESC-CMs) provide a promising source for cell therapy and drug screening. Several high-yield protocols exist for hESC-CM production; however, methods to significantly advance hESC-CM maturation are still lacking. Building on our previous experience with mouse ESC-CMs, we investigated the effects of 3-dimensional (3D) tissue-engineered culture environment and cardiomyocyte purity on structural and functional maturation of hESC-CMs. 2D monolayer and 3D fibrin-based cardiac patch cultures were generated using dissociated cells from differentiated Hes2 embryoid bodies containing varying percentage (48-90%) of CD172a (SIRPA)-positive cardiomyocytes. hESC-CMs within the patch were aligned uniformly by locally controlling the direction of passive tension. Compared to hESC-CMs in age (2 weeks) and purity (48-65%) matched 2D monolayers, hESC-CMs in 3D patches exhibited significantly higher conduction velocities (CVs), longer sarcomeres (2.09 ± 0.02 vs. 1.77 ± 0.01 μm), and enhanced expression of genes involved in cardiac contractile function, including cTnT, αMHC, CASQ2 and SERCA2. The CVs in cardiac patches increased with cardiomyocyte purity, reaching 25.1 cm/s in patches constructed with 90% hESC-CMs. Maximum contractile force amplitudes and active stresses of cardiac patches averaged to 3.0 ± 1.1 mN and 11.8 ± 4.5 mN/mm(2), respectively. Moreover, contractile force per input cardiomyocyte averaged to 5.7 ± 1.1 nN/cell and showed a negative correlation with hESC-CM purity. Finally, patches exhibited significant positive inotropy with isoproterenol administration (1.7 ± 0.3-fold force increase, EC50 = 95.1 nm). These results demonstrate highly advanced levels of hESC-CM maturation after 2 weeks of 3D cardiac patch culture and carry important implications for future drug development and cell therapy studies.
Zhang F, Qiu H, Dong X, Zhang X, Wang C, Li X Life Med. 2025; 1(2):179-195.
PMID: 39871934 PMC: 11748996. DOI: 10.1093/lifemedi/lnac002.
Advanced In Vitro Models for Preclinical Drug Safety: Recent Progress and Prospects.
Nair D, Weiskirchen R Curr Issues Mol Biol. 2025; 47(1).
PMID: 39852122 PMC: 11763796. DOI: 10.3390/cimb47010007.
Cardiac fibroblast BAG3 regulates TGFBR2 signaling and fibrosis in dilated cardiomyopathy.
Wang B, Morsink M, Kim S, Luo L, Zhang X, Soni R J Clin Invest. 2025; 135(1).
PMID: 39744939 PMC: 11684812. DOI: 10.1172/JCI181630.
Multidirectional Filamented Light Biofabrication Creates Aligned and Contractile Cardiac Tissues.
Jones L, Filippi M, Michelis M, Balciunaite A, Yasa O, Aviel G Adv Sci (Weinh). 2024; 11(47):e2404509.
PMID: 39373330 PMC: 11653608. DOI: 10.1002/advs.202404509.
Recent advances in precision nutrition and cardiometabolic diseases.
Martinez-Gonzalez M, Planes F, Ruiz-Canela M, Toledo E, Estruch R, Salas-Salvado J Rev Esp Cardiol (Engl Ed). 2024; 78(3):263-271.
PMID: 39357800 PMC: 11875914. DOI: 10.1016/j.rec.2024.09.003.